Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | ERN1 | O75460 | 7/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 3/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 3/20 | 0.50 |
| ▸ | TYR | P14679 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361643 | 0.85 | CA1 (0.59) | CA1CA2ERN1TRIM24TRIM33 | |
| SCHEMBL29459741 | 0.84 | CA1 (0.69) | CA1CA2ERN1TRIM24TRIM33 | |
| SCHEMBL1003414 | 0.84 | CA1 (0.69) | CA1CA2ERN1TRIM24TRIM33 | |
| SCHEMBL29818698 | 0.84 | CA1 (0.52) | CA1CA2ERN1TRIM24TRIM33 | |
| SCHEMBL1004130 | 0.82 | CA1 (0.61) | CA1CA2ERN1TRIM24TRIM33 | |
| SCHEMBL10023121 | 0.80 | CA1 (0.48) | CA1CA2ERN1TRIM24TRIM33 | |
| SCHEMBL22123331 | 0.79 | CA1 (0.58) | CA1CA2ERN1TRIM24TRIM33 | |
| SCHEMBL29729025 | 0.79 | CA1 (0.59) | CA1CA2ERN1TRIM24TRIM33 | |
| SCHEMBL3345839 | 0.79 | CA1 (0.59) | CA1CA2ERN1TRIM24TRIM33 | |
| SCHEMBL1846692 | 0.78 | ALDH1A1 (0.48) | CA1CA2ERN1ALDH1A1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9872852-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3041822-B1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-3041822-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160194307-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-07-07 | — | — | US | disclosed |
| WO-2015034820-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| EP-2590969-A2 | THERAPEUTIC AGENTS 976 | AstraZeneca AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004588-A2 | THERAPEUTIC AGENTS 976 | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004588-A2 | THERAPEUTIC AGENTS 976 | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194307-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HAVCR2, CD4 | CA1 4004/4885CA2 4733/4885ERN1 3556/4885 |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | TYR, MC2R, MC1R | CA1 4828/4885CA2 4291/4885ERN1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.